Media
Media Inquiries: media@alzpath.bio or 1 844 723 7228
ALZpath News
ALZpath to Present at AAIC Meeting
JULY 16-20, 2023
We are proud to share that we will join prominent researchers evaluating biomarkers for Alzheimer’s Disease that have utilized our cutting-edge pTau217 assay at the Alzheimer’s Association International Conference (AAIC) in Amsterdam. Follow the link below for a list of presentations of their important findings.
ALZpath Featured at AAN Meeting
APRIL 24, 2023
A recent study presented at the annual American Academy of Neurology (AAN) meeting found that the ALZpath pTau217 assay detected elevated pTau217 in Alzheimers Disease with the greatest fold difference for any assay evaluated. Further, the ALZpath pTau217 assay identified Alzheimer’s disease in mild cases, as well as moderate and severe.
Clinical Trials on Alzheimer Disease (CTAD)
DECEMBER 27, 2022
Plasma P-tau217 Picks up Plaques, Tangles, Future Decline
Press Release
NOVEMBER 11, 2022
“ALZpath, Inc.”, an Alzheimer’s Disease Diagnostics and Patient Services Company Announces Novel Validated an Scalable Assay for Detection of Phosphorylated Tau 217 in Blood
ALZpath Press Releases
New Study in JAMA Affirms High Diagnostic Accuracy of ALZpath's pTau217 Test
January 22, 2024
ALZpath Announces Partnership with ADDF for Clinical Alzheimer's Diagnostic Launch
JULY 18, 2023
